Growth/differentiation factor 15 (GDF-15) as new potential serum marker in patients with metastatic colorectal cancer
Language English Country United States Media print
Document type Journal Article
PubMed
29400662
DOI
10.3233/cbm-170792
PII: CBM170792
Knihovny.cz E-resources
- Keywords
- GDF-15, biomarker, colorectal cancer, survival,
- MeSH
- CA-19-9 Antigen blood MeSH
- Adult MeSH
- Kaplan-Meier Estimate MeSH
- Carcinoembryonic Antigen blood MeSH
- Colorectal Neoplasms blood mortality pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Survival Rate MeSH
- Biomarkers, Tumor blood MeSH
- Area Under Curve MeSH
- Prognosis MeSH
- ROC Curve MeSH
- Growth Differentiation Factor 15 blood MeSH
- Aged MeSH
- Sensitivity and Specificity MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- CA-19-9 Antigen MeSH
- GDF15 protein, human MeSH Browser
- Carcinoembryonic Antigen MeSH
- Biomarkers, Tumor MeSH
- Growth Differentiation Factor 15 MeSH
BACKGROUND: GDF-15 is a protein belonging to the transforming growth factor beta superfamily that has a role in regulating inflammatory and apoptotic pathways. High level GDF-15 in tumor tissues and plasma correlate with an increased risk of recurrence and reduced overall survival. OBJECTIVE: The aim of this study was to screen GDF-15 capacity to detecting metastatic CRC and compare it with standard tumor markers CEA and CA19-9. METHODS: We collected serum samples from 97 patients with metastatic colorectal cancer and 79 samples from healthy controls. Serum levels of GDF-15, CEA and CA19-9 were measured by immunochemically. A Kaplan-Meier curve was applied for analysis of survival rates, and a log-rank was used for univariate analysis. RESULTS: Serum levels of GDF-15 were significantly higher in patients with colorectal cancer compared to healthy controls (p< 0.001). In addition, serum levels of GDF-15 correlated with extent of liver involvement and patients with higher GDF-15 levels had significantly worse outcome (p< 0.0001). CONCLUSIONS: Our results show GDF-15 as an effective biomarker in patients with metastatic colorectal cancer with the same sensitivity as CEA. In addition, GDF-15 levels strongly correlate with extension of liver involvement in contrast with CEA.
References provided by Crossref.org
Non-Genomic Hallmarks of Aging-The Review
